COMP <GO>
BBIO vs JAZZ // OPERATING MARGIN
BridgeBio Pharma Inc. (NASDAQ) VS. Jazz Pharmaceuticals plc (Ireland) (NASDAQ) • 15-METRIC TALLY: BBIO 4
— JAZZ 7
▲ OPERATING MARGIN LEADER: JAZZ
LAST: $75.00 (+0.06%) • MKT CAP: $14.61B
operating-margins
-60.00%
LAST: $214.44 (-0.71%) • MKT CAP: $13.92B
operating-margins
-10.10%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BBIO VS. JAZZ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | BBIO | JAZZ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 95.80% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -4.70% | -30.30 | JAZZ | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -3.23% | 9.61% | -12.84 | JAZZ | /fcf-yield <GO> |
| Operating Margin ACTIVE | -60.00% | -10.10% | -49.90 | JAZZ | /operating-margins <GO> |
| Net Profit Margin | -60.00% | -8.30% | -51.70 | JAZZ | /net-margins <GO> |
| Revenue Growth (YoY) | 126.30% | 4.90% | +121.40 | BBIO | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.45 | 1.97 | -1.52 | JAZZ | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 7/9 | -3.00 | JAZZ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 64.0 | 47.0 | +17.00 | BBIO | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.00 | 1.09 | -0.09 | JAZZ | /macro-sensitivity <GO> |
| Forward P/E Multiple | 33.0x | 36.0x | -3.00 | BBIO | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $14.61B | $13.92B | $688.8M | BBIO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | BBIO REV | JAZZ REV | BBIO GROSS % | JAZZ GROSS % | BBIO FCF | JAZZ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $502.1M | $4.27B | 95.8% | — | -$447.0M | $1.30B |
| FY 2024 | $221.9M | $4.07B | 98.3% | — | -$521.7M | $1.36B |
| FY 2023 | $9.3M | $3.83B | — | — | -$528.1M | $919.5M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BBIO // BETA 1.00
JAZZ // BETA 1.09